SRRK News and Press, Scholar Rock Holding Corporation

Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date FDA review...

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility ...

2026-06-25 09:33:33 ET Spinal Muscular Atrophy [SMA] therapies have come a long way in reducing infant mortality from this dread disease. Now a new therapy from Scholar Rock Holding Corporation ( SRRK ) promises to further boost patients by preserving their muscle mass . This is...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced to...

2026-06-18 08:15:08 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for SRRK on June 18, 2026 10:57AM ET. The previous analyst recommendation was Overweight. SRRK was trading at $46.95 at issue of the analyst recommendation. The overall analyst consensus : ...

2026-06-09 12:32:14 ET Scholar Rock Holding Corporation (SRRK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 10:00 AM EDT... Read the full article on Seeking Alpha For further details see: Scholar Rock Holding Corporation (SRRK) Presents at Goldman...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculos...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculos...

2026-05-12 14:20:48 ET Scholar Rock Holding Corporation (SRRK) Bank of America Global Healthcare Conference 2026 May 12, 2026 11:00 AM EDT... Read the full article on Seeking Alpha For further details see: Scholar Rock Holding Corporation (SRRK) Presents at Bank of America G...

2026-05-08 11:30:48 ET Image source: The Motley Fool. Thursday, May 7, 2026 at 8:00 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading